NASDAQ: DHAIDih Holding Us Inc Stock
$1.40+0.17 (+13.82%)
Updated Nov 29, 2024
DHAI Price
$1.40
Fair Value Price
$0.53
Market Cap
$56.76M
52 Week Low
$0.72
52 Week High
$13.90
P/E
N/A
P/B
-1.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.11
Operating Cash Flow
N/A
Beta
0.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DHAI Overview
Aurora Technology Acquisition Corp. is a "blank check" company formed to effect mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or related business combinations. It targets tech companies (artificial intelligence, blockchain, quantum computing, electric vehicles) in the U.S. and Asia. Sponsored by ATAC Sponsor LLC, Aurora Technology was incorporated in 2021 and is based in San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DHAI's potential to beat the market
- DHAI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
DHAI
RankedUnranked of 90
RankedUnranked of 90
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $30.78 | A | |
| $12.29 | A | |
| $19.54 | A |
Be the first to know about important DHAI news, forecast changes, insider trades & much more!
DHAI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DHAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DHAI ($1.40) is overvalued by 163.89% relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DHAI ($1.40) is not significantly undervalued (163.89%) relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DHAI's short-term liabilities ($49.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more DHAI due diligence checks available for Premium users.
Valuation
DHAI fair value
Fair Value of DHAI stock based on Discounted Cash Flow (DCF)
Price
$1.40
Fair Value
$0.53
Overvalued by
163.89%
DHAI ($1.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DHAI ($1.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DHAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
37.55x
Market
27.74x
DHAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.65x
Industry
4.13x
DHAI's financial health
Profit margin
Revenue
$18.2M
Net Income
-$234.0k
Profit Margin
-1.3%
Assets to liabilities
Assets
$38.2M
Liabilities
$72.6M
Debt to equity
-2.11
DHAI's short-term liabilities ($49.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DHAI's short-term assets ($29.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DHAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DHAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$476.0k
Investing
-$188.0k
Financing
-$1.0M
DHAI vs Medical Device Stocks
Dih Holding Us Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.